Kurma Partners closed its fourth and largest venture fund, signaling continued institutional backing for therapeutic pipeline builders. The €215 million fund is raised to pursue disruptive therapeutic solutions and follows prior exits connected to Kurma investments, including acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. On the corporate side, Inventiva filled out its C-suite as the company prepares for a key Phase III readout tied to lanifibranor in MASH. The reshuffle includes a new CFO hire and appointments for chief legal officer and chief people officer, reflecting a common pre-readout posture of tightening governance and operational leadership. Both moves reinforce a theme across biotech funding and operations: capital formation and management depth are being positioned alongside upcoming clinical catalysts.